There is a pressing need for a simple noninvasive test of exocrine pancreatic function for use in children. The pancreolauryl test has been modified by the addition of a second marker (mannitol) to achieve a single day test without the need for two timed urine collections. Six healthy subjects and nine patients with cystic fibrosis were studied. Fluorescein, fluorescein dilaurate, and mannitol were taken by mouth, alone or in combinations, followed by 10 hour urine collections in two hourly aliquots to study the comparative pharmacokinetics of these markers. by the development of a dual marker system which involves the inclusion of a second marker with absorption, distribution, and excretion characteristics similar to that of free fluorescein, to eliminate the second day of the test and to shorten the duration of the collection of urine. Mannitol, which has been used extensively for the measurement of intestinal permeability in infancy and childhood,'"' has been chosen as such a marker.
Abstract
There is a pressing need for a simple noninvasive test of exocrine pancreatic function for use in children. The pancreolauryl test has been modified by the addition of a second marker (mannitol) to achieve a single day test without the need for two timed urine collections. Six healthy subjects and nine patients with cystic fibrosis were studied. Fluorescein, fluorescein dilaurate, and mannitol were taken by mouth, alone or in combinations, followed by 10 hour urine collections in two hourly aliquots to study the comparative pharmacokinetics of these markers. Urinary fluorescein was determined spectrophotometrically and urinary mannitol enzymatically. When fluorescein dilaurate and mannitol were taken together and the results expressed as ratios of percentage fluorescein to percentage mannitol recovery (F:M ratio) (mean (SD)) there was clear discrimination between healthy subjects and those with cystic fibrosis regardless of enzyme replacement treatment (57.3 (18.2) v 3-4 (1-4) v (1-6) respectively). The differences in F:M ratios reached statistical significance in urinary aliquots collected between two and eight hours after marker ingestion. This single day tubeless test will greatly simplify the investigation of the child with suspected exocrine pancreatic dysfunction. ( 10 hours after ingestion of the markers. Six patients with cystic fibrosis did not take their enzyme supplements for the 24 hours preceding the test (CFWO). These six, and three further subjects with cystic fibrosis, were also studied while taking their pancreatic enzyme supplements (CFW). The subjects with cystic fibrosis performed test 6 only.
BIOCHEMICAL MEASUREMENTS
After measurement of volume, a 20 ml aliquot of each urine specimen was frozen at -20°C.
Green, Ausn, Weaver There was a highly significant (p<0 001) difference in total mean (SD) percentage fluorescein recoveries, however (18-7 (3-8) % (controls); 1-2 (0-5)% (CFWO); 1-1 (0-7)% (CFW)) (fig 2) , resulting in a highly snificant difference in total 10 hourly fluorescein to mannitol (F:M) ratios (57-3 (18-2) v 3-4 (1-4) v 3-2 (1-6)) (controls v CFWO and CFW; p<0001) (fig 3) .
When the results were expressed as F:M ratios for each urine aliquot the differences between healthy controls and patients with cystic fibrosis, receiving or not receiving enzymes, were highly significant in aliquots collected between two and eight hours after marker ingestion (figs 3 and 4) (p<O0OOl).
Discussion
Fluorescein dilaurate is a colourless, poorly water soluble synthetic ester which when given by mouth is hydrolysed by aryl esterases of the pancreatic secretions to lauric acid and water soluble fluorescein."9 The latter is absorbed in the small intestine, partly conjugated in the liver, and excreted in the urine where it may be detected spectrophotometrically. In the absence of pancreatic digestion fluorescein dilaurate remains colourless because the opening of the lactone ring, which stabilises the double bonds of one of the phenolic groups responsible for fluorescence, does not occur. Urinary free Mannitol is a hexitol which resists metabolism within the gastrointestinal tract and systemically. It has no affinity for active transport systems,"2123 its distribution is restricted to the extracellular space,24 and it is wholly and solely excreted in the urine with a clearance rate similar to that ofcreatinine.2" It is present in some infant feeds"5 and has proved to be a useful and safe marker to measure changes in the passive intestinal permeability of infants in a variety ofphysiological and pathological disorders.'"7 A dose of 25 mmol was chosen because this had been established as a suitable, safe, and detectable dose in these earlier studies.
By combining fluorescein dilaurate and mannitol in the same test the factors which affect absorption, distribution, and excretion of free fluorescein and mannitol apply equally to both, and changes in the urinary recovery ofthe former compared with the latter (F:M ratio) will be an indirect measure of pancreatic digestion.
The fluorescein dilaurate-mannitol test was well tolerated by all subjects. In contrast with other studies' we did not find the mean mannitol recovery to be significantly higher in patients with cystic fibrosis. Most of the fluorescein and mannitol was recovered within eight hours of ingestion. When fluorescein dilaurate and mannitol were given together and the results were expressed as a fluorescein to mannitol ratio there was clear discrimination between healthy adults and patients with cystic fibrosis, whether they were receiving pancreatic enzyme supplements or not. This indicates that exogenous enzyme preparations do not contain the esterases capable ofcleaving fluorescein dilaurate.
When F:M ratios were calculated for each two hourly urinary aliquot it was clear that from two to eight hours there was a gnificant difference between healthy subjects and patients with cystic fibrosis (fig 3) . The period before two hours probably represents the time taken for the lauric acid residues to be cleaved from fluorescein 
